Cardiac mortality · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Time to heart decompensation · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Disease‐free period at 30, 60 and 90 days · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Overall survival · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Quality of life · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Adverse events · heart failure in patients with Chagas cardiomyopathy
It is very uncertain whether carvedilol changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
Cardiac mortality · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone may leads to lower sudden cardiac death compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with other antiarrhythmics (low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with beta blockers (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with beta blockers (very low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with sotalol (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with sotalol (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
Sudden cardiac death · beta blockers
Amiodarone showed no clear difference in sudden cardiac death compared with beta blockers (low certainty).
1 finding from 1 review
All‐cause mortality · beta blockers
Amiodarone may leads to lower all‐cause mortality compared with beta blockers (low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone showed no clear difference in sudden cardiac death compared with other antiarrhythmics (moderate certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone probably leads to lower all‐cause mortality compared with other antiarrhythmics (moderate certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with placebo or no treatment (very low certainty).
1 finding from 1 review